An Open-label Multicenter Phase 1b Study of JNJ-63723283 a PD-1 Inhibitor Administered in Combination with Apalutamide in Subjects with Metastatic Castration-Resistant Prostate Cancer
Brief description of study
If you have been diagnosed with Metastatic Castration-Resistant Prostate Cancer, you may be qualified for this Phase 1b study. The main goal of the study is to find out how safe and effective the investigational drug JNJ-63723283 and apalutamide (ERLEADA) are when given together to treat patients with prostate cancer. JNJ-63723283 is a new PD-1 inhibitor that is being developed as an immunotherapy.
Clinical Study Identifier: s18-00360
ClinicalTrials.gov Identifier: NCTs18-00360
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
